PAIN
Volume 133, Issue 1 , Pages 210-220 , 15 December 2007

Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial

  • Turo J. Nurmikko

      Affiliations

    • Division of Neurological Science, University of Liverpool, Liverpool, United Kingdom
    • Corresponding Author InformationCorresponding author. Address: Pain Research Institute, Division of Neurological Science, University of Liverpool Clinical Sciences Centre, Lower Lane, Liverpool L9 7AL, United Kingdom. Tel.: +44 (0) 151 529 5820; fax: +44 (0) 151 529 5821.
    • ,
  • Mick G. Serpell

      Affiliations

    • Gartnavel General Hospital, Glasgow, United Kingdom
    • ,
  • Barbara Hoggart

      Affiliations

    • Solihull Hospital, Birmingham, United Kingdom
    • ,
  • Peter J. Toomey

      Affiliations

    • York District Hospital, York, United Kingdom
    • ,
  • Bart J. Morlion

      Affiliations

    • University Hospital, Leuven, Belgium
    • ,
  • Derek Haines

      Affiliations

    • Castle Hill Hospital, Hull, United Kingdom

Received 11 March 2007 ,Revised 21 August 2007 ,Accepted 21 August 2007.

References 

  1. Abrams DI, Jay CA, Shade SB, Vizoso RN, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy. A randomised placebo-controlled trial. Neurology. 2007;68:515–521
  2. Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;11:1153–1169
  3. Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology. 2004;62:218–225
  4. Backonja MA, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831–1836
  5. Banks MH. Validation of the General Health Questionnaire in a young community sample. Psychol Med. 1983;13:349–353
  6. Berman JS, Symonds C, Birch R. Efficacy of cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain. 2004;112:299–306
  7. Bever CT, Grattan L, Panitch PH, Johnson KP. The Brief Repeatable Battery of Neuropsychological Tests for Multiple Sclerosis: a preliminary serial study. Mult Scler. 1995;1:165–169
  8. Costa B, Giagnoni G, Franke C, Trovate AE, Colleani M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol. 2004;143:247–250
  9. Farrar JT, Young JP, La Moreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2000;94:149–158
  10. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48:28–33
  11. Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O, et al. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychol Med. 1997;27:191–197
  12. Gilron I, Bailey JM, Tu D, Holder R, Weaver DF, Houlder RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–1334
  13. Guy GW, Flint ME. A single centre, placebo-controlled, four period, crossover, tolerability study assessing pharmacokinetic effects, pharmacokinetic characteristics and cognitive profiles of as single dose of three formulations of cannabis based medicine extracts (CBMEs) plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes. J Cannab Ther. 2003;3:35–77
  14. Guy GW, Robson P. A Phase I, a double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers. J Cannab Ther. 2003;3:121–152
  15. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett. 1997;221:157–160
  16. Iskedijan M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis pain. Curr Med Res Opin. 2007;23:17–24
  17. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002;6(Suppl A):618
  18. Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol. 2002;42:58S–63S
  19. Karst M, Salim K, Burstein S, Conrad I, Hog C, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. JAMA. 2003;290:1757–1762
  20. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561–564
  21. Meier T, Wassner G, Faust M, Kuntzner T, Ochsner F, Hueppe M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Pain. 2003;106:151–158
  22. Nahas GG, Schwartz IW, Adamec JM, Manger WM. Tolerance of delta 9 THC in the spontaneously hypertensive rat. Proc Soc Exp Biol Med. 1973;142:58–60
  23. Nikolasjen L, Gotrup H Kristensen AG, Jensen TS. Memantine (a N-methyl-d-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blind, cross-over study. Anesth Analg. 2000;91:960–966
  24. Pevalin DJ. Multiple applications of the GHQ-12 in a general population sample: an investigation of long-term retest effects. Soc Psychiatry Psychiatr Epidemiol. 2000;35:508–512
  25. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double-blind, placebo-controlled study. Pain. 2001;94:215–224
  26. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized Controlled Trial of Cannabis Based Medicine in Central Neuropathic Pain due to Multiple Sclerosis. Neurology. 2005;65:812–819
  27. Russo EB, McPartland JM. Cannabis is more than simply Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl). 2003;165:431–432
  28. Sagar DR, Kelly S, Millns PJ, O’Shaughnessey CT, Kendall DA, Chapman V. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci. 2005;22:371–379
  29. Serpell MG. Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndrome: a double-blind, placebo-controlled trial. Pain. 2002;99:557–566
  30. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J. 2004;329:25–38
  31. Tait RC, Chibnall JT, Krause S. The Pain Disability Index: psychometric properties. Pain. 1990;40:171–182
  32. Varvel SA, Wiley JL, Yang R, Bridgen DT, Lomg K, Lichtman AH, et al. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology. 2006;186:226–234
  33. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects in multiple sclerosis? A double-blind, randomised, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434–441
  34. Wallace M, Braun J, Schulters G. Postdelivery of alfentanil and ketamine has no effect on intradermal capsaicin induced pain and hyperalgesia. Clin J Pain. 2002;18:373–379
  35. Wallace MS, Magnusson S, Ridgeway B. Efficacy of oral mexiletine for neuropathic pain: a double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med. 2000;25:459–467
  36. Wallace MS, Rowbotham MC, Katz NP, Dworkin DH, Dotson RM, Galer BS, et al. A randomized, double-blind, placebo-controlled trial of glycine antagonist in neuropathic pain. Neurology. 2002;59:1694–1700
  37. Werneke U, Goldberg DP, Yalsin I, Ustun BT. The stability of the factor structure of the General Health Questionnaire. Psychol Med. 2000;30:823–829
  38. Witkin JM, Tzavara ET, Nomikos GG. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol. 2005;16:315–331
  39. Woolf CJ. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci. 2004;74:2605–2610
  40. Zajisec J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;363:1517–1526

PII: S0304-3959(07)00464-2

doi: 10.1016/j.pain.2007.08.028

PAIN
Volume 133, Issue 1 , Pages 210-220 , 15 December 2007

Article Tools

* Image Usage & Resolution